Newsroom

Although there are many female virologists, microbiologists, and infectious diseases researchers in leadership positions at German universities and research institutes, they are usually not in the public eye. The inaccurate perception of few women being science experts was particularly evident during the first phase of the COVID-19 pandemic, where it was primarily male virologists positioning themselves as advisors to policymakers in the media. HZI virologist Melanie Brinkmann is a founding member of the newly established association Infect-Net.

The endogenous molecule itaconic acid has antiviral and anti-inflammatory effects, as researchers from TWINCORE have recently shown. In cooperation with scientists from the Helmholtz Centre for Infection Research in Braunschweig and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), they have now investigated the closely related substance citraconic acid. The result: Citraconic acid protects cells through antioxidant and anti-inflammatory properties. It also inhibits the release of flu viruses from human cells. They published these results in the journal Nature Metabolism.

The LOKI pilot project was launched on 1 July 2022 under the leadership of the Helmholtz Centre for Infection Research (HZI) and in collaboration with the Academy for Public Health Services (AÖGW), the CISPA Helmholtz Center for Information Security, the Forschungszentrum Jülich (FZJ), the German Aerospace Center (DLR) and the Helmholtz Centre for Environmental Research (UFZ). The goal: To provide health authorities with a local early warning system for epidemiologically relevant infection outbreaks in the future - customised and practical.

Hepatitis D is by far the most severe form of chronic viral hepatitis frequently leading to liver failure, hepatocellular carcinoma and death. However, there is very limited knowledge on disease pathophysiology and host-virus interactions explaining the large interindividual variability in the course of hepatitis D. Hannover Medical School (MHH) with its Department of Gastroenterology, Hepatology and Endocrinology and its Centre for Individualised Infection Medicine (CiiM), a joint institution of MHH and the Helmholtz Centre for Infection Research (HZI) in Braunschweig, coordinates an international project for an unbiased screening of a large multicenter cohort of well-defined HDV-infected patients to better understand individual factors determining the outcome of infection and to identify subjects benefitting from currently available treatments. In a highly competitive call for proposals, the D-SOLVE consortium (“Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D”) has received four-year funding of 6.75 million euros from the Horizon 2020 EU Horizon Call „Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)“ of the European Union. In addition to the MHH as project partner and coordinator, institutions from Germany, France, Italy, Sweden and Romania are involved in the project.

The coronavirus SARS-CoV-2 can infect various body tissues. While the detection of the virus in the nasopharynx is established as a diagnostic method, the amount of virus found there does not allow a prognosis of the course of the disease. In a recent study, a research team from the Helmholtz Centre for Infection Research (HZI) in cooperation with the University of Rijeka, Croatia, investigated the correlation between the viral load in different tissues and the mortality of patients with a severe course of COVID-19. The researchers show for the first time that viral load can contribute to clinical prognosis, as a higher viral load in the lungs at the time of ventilation correlates with an increased risk of death. In this interview, first author Henrike Maaß and study leader Prof Luka Cicin-Sain, head of the department “Viral Immunology” at HZI, talk about the research results that were published in the journal Viruses MDPI.

The development of new active substances against pathogenic bacteria, parasites, fungi and viruses is gaining importance, as established antiinfectives are becoming increasingly ineffective due to the development of resistance. At the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a team led by Prof Rolf Müller has optimized an antimicrobial natural product that is active against infections with both, the hospital acquired MRSA pathogen and the malaria causing parasite, for preclinical research and future potential application in humans. The researchers have published their results in the journal Angewandte Chemie International Edition.